N-terminal pro-B-type Natriuretic Peptides' Prognostic Utility Is Overestimated in Meta-analyses Using Study-specific Optimal Diagnostic Thresholds
Danielle Potgieter, Dale Simmers, Lisa Ryan, Bruce M Biccard, Giovanna A Lurati-Buse, Daniela M Cardinale, Carol PW Chong, Miloslaw Cnotliwy, Sylvia I Farzi, Radmilo J Jankovic, Wen Kwang Lim, Elisabeth Mahla, Ramaswamy Manikandan, Anna Oscarsson, Michael P Phy, Sriram Rajagopalan, William J Van Gaal, Marek Waliszek, Reitze N Rodseth
Anesthesiology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Dr. Mahla has spoken for and received consulting fees from CLS Behring Biotherapies for Life (Vienna, Austria), Astra Zeneca (Vienna, Austria), and Boehringer Ingelheim (Ingelheim, Germany). She has received study grants from CLS Behring Biotherapies for Life and Novo Nordisk Pharma GmbH (Vienna, Austria). The other authors declare no competing interests.